Deep Track (COAG) reports 8.15% ownership in Hemab Therapeutics

Rhea-AI Filing Summary

Hemab Therapeutics Holdings, Inc. passive ownership disclosure: Deep Track-related entities reported beneficial ownership positions in Hemab common stock totaling up to 3,600,996 shares (8.15%) as of May 8, 2026. The filing states the ownership percentages use 44,192,910 shares outstanding as of May 1, 2026.

The Schedule 13G is a joint filing by Deep Track Capital, LP; Deep Track Biotechnology Master Fund, Ltd.; Deep Track Special Opportunities Fund, LP; and David Kroin, identifying shared voting and dispositive power over reported holdings.

Insights

Institutional Ownership Analyst

Passive 13G shows Deep Track group holds a meaningful minority stake.

The filing lists 3,600,996 shares (8.15%) beneficially owned by Deep Track Capital-related parties, based on 44,192,910 shares outstanding as of May 1, 2026. Voting and dispositive power is reported as shared across entities and David Kroin.

Impact depends on whether holdings remain passive; subsequent filings (amendments or a Schedule 13D) would indicate an active stance. Timing for changes is not disclosed in the excerpt.

Corporate Governance Specialist

Joint filing signals coordinated disclosure, not necessarily control.

The statement is a joint Schedule 13G under Rule 13d-1(k) and notes the entities agreed to file jointly. The filing identifies Deep Track Capital, LP as the relevant entity for control-person attribution of David Kroin.

Governance implications hinge on any future changes in voting alignment or additional filings; current data show shared power, not sole control.

Key Figures

Shares outstanding: 44,192,910 shares Deep Track Capital beneficial ownership: 3,600,996 shares Deep Track Capital ownership pct: 8.15% +2 more

5 metrics

Shares outstanding 44,192,910 shares as of May 1, 2026

Deep Track Capital beneficial ownership 3,600,996 shares reported beneficially owned amount (covering shared power)

Deep Track Capital ownership pct 8.15% percent of class based on 44,192,910 shares outstanding

Deep Track Biotechnology Master Fund stake 2,981,198 shares reported beneficial ownership (6.75%)

Deep Track Special Opportunities Fund stake 619,798 shares reported beneficial ownership (1.40%)

Key Terms

Schedule 13G, beneficially owned, shared dispositive power, Rule 13d-1(k)

4 terms

Schedule 13G regulatory

"Item 1. ... Name of issuer: Hemab Therapeutics Holdings, Inc."

A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.

beneficially owned financial

"Item 4. | Ownership (a) | Amount beneficially owned: 3,600,996"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

shared dispositive power regulatory

"6 | Shared Voting Power 3,600,996.00 ... 8 | Shared Dispositive Power 3,600,996.00"

Rule 13d-1(k) regulatory

"JOINT FILING STATEMENT PURSUANT TO RULE 13d-1(k)"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/08/2026 - 04:18 PM Learn about SEC filing dates

FAQ

What stake does Deep Track report in Hemab Therapeutics (COAG)?

Deep Track-related parties report beneficial ownership of 3,600,996 shares (8.15%) in Hemab common stock, using 44,192,910 shares outstanding as of May 1, 2026. The filing attributes shared voting and dispositive power to the reporting entities.

Which entities filed the Schedule 13G for Hemab (COAG)?

The joint Schedule 13G was filed by Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd., Deep Track Special Opportunities Fund, LP, and David Kroin, with Deep Track Capital, LP identified as the relevant entity for control-person attribution.

What outstanding share count does the filing use for Hemab (COAG)?

The filing states an outstanding share count of 44,192,910 shares as of May 1, 2026, taken from the issuer's prospectus filed on that date. That figure is used to calculate the reported ownership percentages.

Does the Schedule 13G indicate active control or passive ownership for COAG?

The Schedule 13G is a passive reporting form under Rule 13d-1(k) and lists shared voting and dispositive power. The filing does not assert active control; any change to an active intent would typically be reflected by a later Schedule 13D or amendment.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Hemab Therapeutics Holdings, Inc.

(Name of Issuer)

Common stock, $0.0001 par value per share

(Title of Class of Securities)

423494103

(CUSIP Number)

05/01/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 423494103

1

Names of Reporting Persons

Deep Track Capital, LP

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 3,600,996.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 3,600,996.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

3,600,996.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

8.15 %

12

Type of Reporting Person (See Instructions)

IA, OO

SCHEDULE 13G

CUSIP Number(s): 423494103

1

Names of Reporting Persons

Deep Track Biotechnology Master Fund, Ltd.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

CAYMAN ISLANDS

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 2,981,198.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 2,981,198.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

2,981,198.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

6.75 %

12

Type of Reporting Person (See Instructions)

CO

SCHEDULE 13G

CUSIP Number(s): 423494103

1

Names of Reporting Persons

David Kroin

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 3,600,996.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 3,600,996.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

3,600,996.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

8.15 %

12

Type of Reporting Person (See Instructions)

HC, IN

SCHEDULE 13G

CUSIP Number(s): 423494103

1

Names of Reporting Persons

Deep Track Special Opportunities Fund, LP.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 619,798.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 619,798.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

619,798.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

1.40 %

12

Type of Reporting Person (See Instructions)

PN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Hemab Therapeutics Holdings, Inc.
(b)	Address of issuer's principal executive offices: 101 Main Street, Suite 1220, Cambridge, MA 02142
Item 2.
(a)	Name of person filing: (i) Deep Track Capital, LP (ii) Deep Track Biotechnology Master Fund, Ltd. (iii) David Kroin (iv) Deep Track Special Opportunities Fund, LP.
(b)	Address or principal business office or, if none, residence: (i) 200 Greenwich Ave, 3rd Floor, Greenwich, CT 06830 (ii) c/o Walkers Corporate Limited, 190 Elgin Ave, George Town, KY1-9001, Cayman Islands (iii) c/o Deep Track Capital, LP, 200 Greenwich Ave, 3rd Floor, Greenwich, CT 06830 (iv) c/o Deep Track Capital, LP, 200 Greenwich Ave, 3rd Floor, Greenwich, CT 06830
(c)	Citizenship: (i) Delaware (ii) Cayman Islands (iii) United States (iv) Delaware
(d)	Title of class of securities: Common stock, $0.0001 par value per share
(e)	CUSIP Number(s): 423494103
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 3,600,996
(b)	Percent of class: 8.15%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 0
	(ii) Shared power to vote or to direct the vote: 3,600,996
	(iii) Sole power to dispose or to direct the disposition of: 0
	(iv) Shared power to dispose or to direct the disposition of: 3,600,996
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary. Deep Track Capital, LP is the relevant entity for which David Kroin may be considered a control person.
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Deep Track Capital, LP

Signature:	/s/ David Kroin
Name/Title:	David Kroin, Managing Member of the General Partner of the Investment Adviser
Date:	05/08/2026

Deep Track Biotechnology Master Fund, Ltd.

Signature:	/s/ David Kroin
Name/Title:	David Kroin, Director
Date:	05/08/2026

David Kroin

Signature:	/s/ David Kroin
Name/Title:	David Kroin
Date:	05/08/2026

Deep Track Special Opportunities Fund, LP.

Signature:	/s/ David Kroin
Name/Title:	David Kroin, Managing Member of the General Partner of the Investment Adviser of Deep Track Special Opportunities Fund, LP
Date:	05/08/2026

Exhibit Information

Item 4: Information with respect to the Reporting Persons' ownership of the Common Stock as of May 8, 2026, is incorporated by reference to items (5) - (9) and (11) of the cover page of the respective Reporting Person. The amount beneficcially owned by each Reporting Person is determined using 44,192,910 shares outstanding as of May 1, 2026, as reported by the issuer on its Prospectus filed with the SEC on May 1, 2026. JOINT FILING STATEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on SCHEDULE 13G, is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on SCHEDULE 13G, shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate. Dated: May 8, 2026 Deep Track Capital, LP By: /s/ David Kroin David Kroin, Managing Member of the General Partner of the Investment Adviser Deep Track Biotechnology Master Fund, Ltd. By: /s/ David Kroin David Kroin, Director David Kroin By: /s/ David Kroin David Kroin Deep Track Special Opportunities Fund, LP. By: /s/ David Kroin David Kroin, Managing Member of the General Partner of the Investment Adviser of Deep Track Special Opportunities Fund, LP